Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Docusign Inc (DOCU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Docusign Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Docusign Inc trades at $49.66 (market cap $9.39B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.2× Docusign Inc's market cap. Which is the better fit depends on your goals.
| ALNY | DOCU | |
|---|---|---|
Market Cap | $39.89B | $9.39B |
Sector | Health | Technology |
52-Week High | $491.22 | $85.01 |
52-Week Low | $278.09 | $41.75 |
Enterprise Value | $38.15B | $8.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
DOCU trades at $49.18, up 0.86% today, with a bullish technical signal from moving averages and strong support near $47. The company reported Q1 2026 EPS of $1.09, beating estimates, and maintains robust gross margins of 79.4%. Recent partnerships with Perplexity and Slack highlight growth in intelligent agreement management, while revenue guidance for 2026 stands at $3.3 billion.
Outlook remains positive with a consensus price target of $55.40, though high valuation multiples (P/E 31.94) and overbought RSI levels pose near-term risks. Competitive pressures in SaaS and reliance on subscription growth are key watchpoints for investors seeking exposure to DOCU's profitable expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →
